Navigation Links
Thomson Reuters Empowers Drug Development and Clinical Professionals to Develop Better, Faster Clinical Trials with Best-in-Class Intelligence Solution
Date:12/5/2012

PHILADELPHIA, Dec. 5, 2012 /PRNewswire/ -- The IP & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced  a preview of its newest intelligence solution, Thomson Reuters Cortellis™ for Clinical Trials Intelligence. Scheduled for release in early 2013, this capability will provide drug development and clinical professionals with the critical information necessary to evaluate market opportunities, identify potential barriers, and establish informed decisions about clinical trial design and operations. 

Cortellis for Clinical Trials Intelligence is the latest information solution offered through Thomson Reuters Cortellis, the industry's premier Life Sciences information delivery platform. It has the broadest remit of any clinical trials database including a 45-year history of clinical outcomes, as well as the latest market competitive activity from established and emerging markets such as China, India and Brazil. It is the only solution that enables a customer to integrate their proprietary research data with comprehensive clinical trials protocols and outcomes, drug pipeline, biomarker, regulatory, financial and patent information from Thomson Reuters. With its integrated analytics tools and visualizations, users will have greater opportunities to maximize the value of clinical trial content to inform internal strategy and decision-making.  

"Cortellis for Clinical Trials Intelligence provides comprehensive clinical trial protocols and outcomes with global reach and integrates with other key intelligence areas – such as patents and literature – to allow for the broadest possible perspectives and actionable insights," said Jon Brett-Harris, ex
'/>"/>

SOURCE Thomson Reuters
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
2. Thomson Reuters Finds Increase in New Research for Neglected Tropical Diseases
3. Thomson Reuters Speeds Regulatory Decision Making with New Pharmaceutical Intelligence Solution
4. Thomson Reuters Annual Pharmaceutical Factbook Reveals Key Insights into Current Trends
5. Thomson Reuters Welcomes Inova Software to Its Partner Ecosystem for Life Sciences
6. Roche Selects Thomson Reuters to Transform the Management of Its Intellectual Property Assets
7. Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler
8. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
9. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
10. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
11. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  Eli Lilly and ... Stanley Global Healthcare Conference on Thursday, September 17, 2015. ... president of Lilly Oncology and Richard Gaynor , ... affairs for Lilly Oncology, will participate in a fireside ... A live audio webcast will be available on ...
(Date:8/27/2015)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the ... and patent-protected processes to develop and market advanced ... Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors ... inaccuracies in the press release issued by the ... from the Patent Trial and Appeal Board ("PTAB"). ...
(Date:8/27/2015)... 2015  Hill-Rom Holdings, Inc., (NYSE: HRC ) ... the Morgan Stanley Global Healthcare Conference on September 16, ... invited to listen to the live discussion via the ... at https://cc.talkpoint.com/morg007/091615a_ae/?entity=49_UCJPU8N . A recorded replay ... the conclusion of the live event and accessible via ...
Breaking Medicine Technology:Lilly to Participate in Morgan Stanley Global Healthcare Conference 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 4
... Significance, FRAZER, Pa., May 01, 2007 /PRNewswire-FirstCall/ ... presented today at the 59th Annual,Meeting of ... highlights,data demonstrating that FENTORA(R) (fentanyl buccal tablet) ... pain in patients,with neuropathic pain who are ...
... Inc. (NYSE:DNA),and Biogen Idec, Inc. (Nasdaq:BIIB) announced ... study of Rituxan(R) (rituximab) in,patients with relapsing-remitting ... American Academy of Neurology annual meeting,held in ... targets and,selectively depletes CD20-positive B-cells., "There remains ...
Cached Medicine Technology:Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 2Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 3Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 4Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 5Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 6Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 7Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 2Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 3Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 4Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 5Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 6
(Date:8/28/2015)... , ... August 28, 2015 , ... ... announce its collaboration with coffee connoisseur and Emmy-nominated actress, Sofia Vergara, and unveil ... features revolutionary Thermal Flavor Extraction™ technology, which delivers a variety of sizes and ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Dual Eligibles Database have added comprehensive information on two new duals programs: ... a December 2015 launch; and Idaho’s partnership to revamp Blue Cross of ...
(Date:8/28/2015)... Louis, MO (PRWEB) , ... August 28, 2015 ... ... in testosterone lawsuits now consolidated as MDL 2545, Testosterone Replacement Therapy ... of a cap on the number of custodial files the PSC may receive ...
(Date:8/28/2015)... ... ... Super-Sod launched their new website this summer. The new user-friendly ... the responsive web design. Website users will now have an improved browsing experience on ... sod, sign-up for the monthly turf-tips email, and find a local Super-Sod store all ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... approach to medicine through health promotion and disease prevention, improving a patient’s quality ... prevalent diseases in the community, including heart disease, cancer, diabetes, HIV/AIDS, STDs, and ...
Breaking Medicine News(10 mins):Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 4Health News:Health Clinic Opening and Public Art Unveiling 2
... Key West Spa ... ... award-winning Jala Spa at Hyatt,s Key West Resort is inviting couples to slip ... the Beach" spa treatment. , , , , ,The reflexology-inspired experience at the West ...
... ... "The View" hits radio on July 6th. , ... Atlanta, GA (PRWEB) July 7, 2010 -- Sponsored ... and Southeast this summer for Ryan Hamner Presents: “Hear the Heart” Summer Tour 2010. ...
... ... interactive solutions to include SMS / Text Messaging. , ... Buffalo, NY (Vocus) July 7, 2010 -- IVR Technology Group (ITG) ... / Text Messaging . With this new addition to their product line up, they ...
... Obesity ... creator of the Zone Diet. , ... Boston (Vocus) July 6, 2010 -- Appearing on The Mel Robbins Show , ... bestselling author of The Zone, detailed the underlying causes of America’s obesity crisis and talked ...
... length of leukocyte telomeres chromosome markers of biological aging ... death from cancer, according to a study in the July ... type of blood cell. Telomeres are a structure at ... stability of the chromosome. Genetic factors and environmental stressors can ...
... shown that cognitive therapy is an effective treatment for ... therapists, training and expertise plays in making treatment successful. ... more symptom improvement when their therapists more competently follow ... also suggests therapist competence may be a particularly important ...
Cached Medicine News:Health News:Relax, Recharge And Reflex This Summer At A Leading Key West Resort 2Health News:Ryan Hamner's Free Hear The Heart Tour Sweeping The South Four-Time Cancer Survivor, Sings Hope To Others 2Health News:IVR Technology Group Announces MobileMarketing123.com 2Health News:Zone Diet Creator Dr. Sears Discusses Obesity Causes and Solutions on Mel Robbins Radio Show 2Health News:Length of biological marker associated with risk of cancer 2Health News:Therapist competence matters -- and more for some patients than others 2Health News:Therapist competence matters -- and more for some patients than others 3
... The Cordis biopsy forceps are designed for ... Biopsy Forceps consist of a 3-pull ring handle, ... The flexible thumb ring rotates to accommodate any ... cutting jaws closed. The jaws are opened by ...
... The LEAD EXTRACTION System is a ... in the percutaneous removal of cardiac leads ... used in both "superior" and "femoral" approach ... Locking Stylet, newest in locking stylet technology, ...
4-Strand Basket Retriever was developed to facilitate recovery of foreign objects from within the neuro, peripheral, and cardiovasculature, the In-Time Retrieval Device features an integrated corewir...
... the percutaneous retrieval of indwelling catheters, cardiac leads, ... other foreign objects. A transfemoral grasping tool ... body. It is delivered to the vicinity of ... cannula that is placed coaxially within a larger ...
Medicine Products: